Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 23,109.0 | 20,370.0 | 11,953.0 | 10,992.0 | 10,770.0 | 10,221.0 | 9,183.0 | 8,979.0 |
| Revenue growth | 13.4% | 70.4% | 8.7% | 2.1% | 5.4% | 11.3% | 2.3% | -0.9% |
| Cost of goods sold | 9,396.0 | 9,050.0 | 5,340.0 | 4,804.0 | 4,764.0 | 4,815.0 | 4,177.0 | 3,862.0 |
| Gross profit | 13,713.0 | 11,320.0 | 6,613.0 | 6,188.0 | 6,006.0 | 5,406.0 | 5,006.0 | 5,117.0 |
| Gross margin | 59.3% | 55.6% | 55.3% | 56.3% | 55.8% | 52.9% | 54.5% | 57.0% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 294.0 | 273.0 | 137.0 | 102.0 | 94.0 | | | |
| Research and development | | | | | | | 135.0 | 115.0 |
| General and administrative | 1,442.0 | 1,252.0 | 433.0 | 365.0 | 369.0 | 288.0 | 322.0 | 313.0 |
| EBITA | 9,385.0 | 7,253.0 | 4,543.0 | 4,337.0 | 3,975.0 | 3,820.0 | 3,359.0 | 3,389.0 |
| EBITA margin | 40.6% | 35.6% | 38.0% | 39.5% | 36.9% | 37.4% | 36.6% | 37.7% |
| Amortization of intangibles | 574.0 | 685.0 | 164.0 | 131.0 | 142.0 | 150.0 | 105.0 | 91.0 |
| EBIT | 8,811.0 | 6,568.0 | 4,379.0 | 4,206.0 | 3,833.0 | 3,670.0 | 3,254.0 | 3,298.0 |
| EBIT margin | 38.1% | 32.2% | 36.6% | 38.3% | 35.6% | 35.9% | 35.4% | 36.7% |
| Pre-tax income | 7,993.0 | 5,473.0 | 4,019.0 | 4,060.0 | 3,326.0 | 3,500.0 | 2,917.0 | 3,127.0 |
| Income taxes | 1,556.0 | 981.0 | 782.0 | 803.0 | 911.0 | 1,058.0 | 794.0 | 921.0 |
| Tax rate | 19.5% | 17.9% | 19.5% | 19.8% | 27.4% | 30.2% | 27.2% | 29.5% |
| Net income | 6,033.0 | 4,184.0 | 3,028.0 | 3,063.0 | 2,220.0 | 2,259.0 | 1,936.0 | 1,983.0 |
| Net margin | 26.1% | 20.5% | 25.3% | 27.9% | 20.6% | 22.1% | 21.1% | 22.1% |
| |
| Diluted EPS | $4.47 | $3.08 | $3.71 | $3.91 | $2.74 | $2.77 | $2.55 | $2.72 |
| Shares outstanding (diluted) | 1,349.4 | 1,358.3 | 815.2 | 783.5 | 811.0 | 814.9 | 757.8 | 728.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|